PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease

Area of Science:

• Immunology
• Autoimmunity
• Cancer Immunotherapy

Background:

• Immune-checkpoint molecules are crucial for balancing immune responses and preventing autoimmunity.
• Modulating immune checkpoints impacts both tumor-specific and self-specific immune reactions, as seen in cancer therapy and immunotherapy side effects.
• There is growing interest in targeting immune checkpoints for autoimmune and rheumatological diseases.

Purpose of the Study:

• To explore the therapeutic potential of targeting immune-checkpoint molecules for autoimmune diseases.
• To investigate the role of PD-1, BTLA, and TIGIT in inducing immune tolerance.
• To highlight the importance of understanding these molecules' functions in immune cells for clinical translation.

Main Methods:

• Pre-clinical models were used to test the targeting of immune-checkpoint molecules.
• Clinical trials were initiated for some targeted immune-checkpoint molecules.
• Analysis of immune cell populations, particularly T cells, across different diseases was emphasized.

Main Results:

• Targeting immune-checkpoint molecules PD-1, BTLA, and TIGIT demonstrated therapeutic promise in pre-clinical settings.
• Some targeted immune-checkpoint therapies have progressed to clinical trials.
• The modulation of these receptors profoundly affects immune responses.

Conclusions:

• Targeting immune checkpoints like PD-1, BTLA, and TIGIT offers a promising strategy for inducing immune tolerance in autoimmune diseases.
• A thorough understanding of immune checkpoint receptor function in various immune cells and diseases is essential for successful clinical application.
• Further research is needed to fully translate these findings into effective treatments for autoimmune conditions.